As only 20% of hematologic tumors carry P53 mutations, yet the activity profiles favor hematologics over solid tumors, even ovarian cancers, where up to 80% of patients carry P53 mutations, the activities for both compounds appear to extend beyond their direct impact upon P53. This evidence concerns the gene TP53 and hematopoietic and lymphoid system neoplasm.